Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Boston Scientific Corporation    BSX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Boston Scientific Corporation : BSX, ABT, ZMH, and ETRM Under StockCall’s Microscope

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/02/2013 | 02:00pm CET

StockCall.com Provides Stock Research on Boston Scientific Corp., Abbott Laboratories, Zimmer Holdings Inc., and EnteroMedics Inc.

New York City, New York -- (May 02, 2013)

The Supreme Court, last year, upheld the Affordable Care Act (ACA), which is the biggest overhaul of the healthcare industry in decades. While the healthcare industry has generally supported ACA, some features of the act have faced criticism. One such feature is the 2.3% tax on gross U.S. sales of medical devices. Medical appliances & equipment makers say that the tax will lead to higher costs for them, hurting innovation. While the Senate voted in favor of repealing the 2.3% tax, it is unlikely that the tax will be repealed. Shares of medical appliances & equipment companies ended mostly lower on Wednesday, tracking losses in the broad market. Among the major movers were Boston Scientific Corporation (NYSE: BSX), Abbott Laboratories (NYSE: ABT), Zimmer Holdings Inc. (NYSE: ZMH), and EnteroMedics Inc. (NASDAQ: ETRM). StockCall has released full comprehensive research on BSX, ABT, ZMH, and ETRM and these free technical analyses can be downloaded by signing up at

www.stockcall.com/technicalanalysis

Shares of Boston Scientific Corporation fluctuated between gains and losses on Wednesday before finishing the day flat at $7.49 on volume of 12.95 million. Shares of the company have traded sideways this week. However, year-to-date, the stock has had an excellent run, jumping more than 30.70% as compared to a gain of nearly 11% for the S&P 500. BSX?s shares are currently trading nearly 5.80% below their 52-week high. Free technical analysis on BSX available by signing up at

www.StockCall.com/BSX050213.pdf

Shares of Abbott Laboratories edged lower in Wednesday?s trading session, however, the losses were limited. The stock ended the day 0.08% lower at $36.89 on volume of 5.46 million after trading between $36.62 and $37.20. Despite the pullback, Abbott?s shares are up nearly 1.20% for the week. The stock has gained more than 18.50% so far in 2013, outperforming the S&P 500. However, shares of ABT have been struggling to break through $37.50 resistance level. The stock is currently trading well above its 50-day and 200-day moving averages. Register today and access the free research on ABT at

www.StockCall.com/ABT050213.pdf

Zimmer Holdings Inc.?s shares also slipped in trading on Wednesday, tracking losses in the broad market. The stock closed 1.50% lower at $75.30 on volume of 617,800. Despite the pullback, the company?s shares are currently trading close to their 52-week high of $77.53. Shares of ZMH have been facing resistance at around $76.50. The stock currently has strong support at around $73. Zimmer?s shares are currently trading well above their 50-day and 200-day moving averages which suggests that market sentiment is bullish on the stock. The positive trend is further confirmed by recent volume activity. The free report on ZMH can be downloaded by signing up now at

www.StockCall.com/ZMH050213.pdf

Shares of EnteroMedics Inc. tumbled in Wednesday?s trading session after the company reported its financial results for the first quarter. The stock closed 9.59% lower at $0.868 on above average volume of 601,300 after touching an intra-day low of $0.86. Shares of ETRM are currently trading close to their 52-week low of $0.81. Year-to-date, the stock has now fallen nearly 69%. Most of the losses came in mid-February when the stock saw a huge sell-off. EnteroMedics? shares have now slipped below their 50-day moving average. Free report on ETRM can be accessed by registering at

www.StockCall.com/ETRM050213.pdf

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at

www.stockcall.com

Contact Person:

William T. Knight

Email: info@stockcall.com

Contact Number: (646) 396-9857 (9:00 am EST ? 01:30 pm EST)


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BOSTON SCIENTIFIC CORPORAT
01/19 BOSTON SCIENTIFIC : Trademark Application for "DIRECTSENSE" Filed by Boston Scie..
01/19 BOSTON SCIENTIFIC : Joanna Engelke Joins Halloran Consulting Group as Managing D..
01/18 BOSTON SCIENTIFIC : Contract award - 65-- defibrillator-boston scientific
01/18 BOSTON SCIENTIFIC : $26,000 Federal Contract Awarded to Boston Scientific
01/10 CUTERA : Names James A. Reinstein as its Next President and CEO
01/10 BOSTON SCIENTIFIC : $26,500 Federal Contract Awarded to Boston Scientific
01/08DJCorrection to Parkinson's Therapy Story
01/08DJParkinson's Therapy Gets Fresh Look From Device Makers
01/08DJParkinson's Therapy Gets Fresh Look From Device Makers
01/08DJParkinson's Therapy Gets Fresh Look From Device Makers
More news
Sector news : Advanced Medical Equipment & Technology - NEC
01/19 Davos CEOs 'go local' on supply chain in Trump era
2016 Philips, Infineon lose appeal against EU cartel fines
2016 GRIFOLS : Spain's Grifols plans to refinance debt in first quarter 2017 after Ho..
2016 GRIFOLS : to buy Hologic's stake in blood screening JV for $1.85 billion
2016 Chinese bidders walk away from Osram takeover - sources
More sector news : Advanced Medical Equipment & Technology - NEC
News from SeekingAlpha
01/11 Boston Scientific (BSX) presents at 35th Annual J.P. Morgan Healthcare Confer..
01/10 Boston Sci expects to launch Lotus Edge heart valve in U.S. next year; shares..
2016 ABBOTT LABORATORIES : More Insiders Buy As Acquisition Uncertainties Likely To C..
2016 Neovasc Was Brilliant In Taking Advantage Of A Desperate Boston Scientific, B..
2016 Boston Scientific closes Neovasc transaction
Advertisement
Financials ($)
Sales 2016 8 355 M
EBIT 2016 1 987 M
Net income 2016 741 M
Debt 2016 4 735 M
Yield 2016 -
P/E ratio 2016 46,07
P/E ratio 2017 25,07
EV / Sales 2016 4,46x
EV / Sales 2017 4,01x
Capitalization 32 517 M
More Financials
Chart BOSTON SCIENTIFIC CORPORAT
Duration : Period :
Boston Scientific Corporat Technical Analysis Chart | BSX | US1011371077 | 4-Traders
Full-screen chart
Technical analysis trends BOSTON SCIENTIFIC...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 27,5 $
Spread / Average Target 15%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Michael F. Mahoney Chairman, President & Chief Executive Officer
Edward Mackey Executive Vice President-Operations
Daniel J. Brennan Chief Financial Officer & Executive Vice President
Keith D. Dawkins Global Chief Medical Officer & Executive VP
Nelda J. Connors Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BOSTON SCIENTIFIC CORP..10.40%32 571
THERMO FISHER SCIENTIF..2.28%57 144
DANAHER CORPORATION3.55%56 159
PHILIPS-2.19%28 060
INTUITIVE SURGICAL, IN..3.77%25 692
ILLUMINA, INC.25.41%23 685
More Results